SNU-398 (ATCC® CRL-2233)

Organism: Homo sapiens, human  /  Tissue: liver  /  Disease: hepatocellular carcinoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue liver
Product Format frozen
Morphology epithelial
Culture Properties mixed adherent and floating
Biosafety Level 2  [Cells contain Hepatitis B virus]

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease hepatocellular carcinoma
Age 42 years
Gender male
Ethnicity Asian
Karyotype aneuploid; modal number = 62

SNU-398 was derived in 1990 by J.-G. Park and associates from an anaplastic hepatocellular carcinoma taken from a Korean patient who had been treated by transcatheter arterial embolization with lipoidol plus a combination of doxorubicin and mitomycin-C.

Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat-inactivated fetal bovine serum. After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum.

Clinical Data
42 years

Antigen Expression
Blood Type O; Rh +

Grossly, the original tumor was single nodular with perinodular extensions.

Histologically, it was trabecular type.

The cultured cells are multinucleated, and maintain the production of intracytoplasmic hyaline globules as seen in the original tumor.

Hepatitis B virus (HBV) DNA was detected by Southern blot hybridization.
HBV genomic RNA was not expressed.
Complete Growth Medium RPMI 1640 medium, 90%; heat-inactivated fetal bovine serum, 10%
Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. This is a cell line that grows as both attached and suspended cells. The suspended cells are viable and should not be discarded. Recover the suspended cells by gentle centrifugation (125 x g) for subculture along with the adherent cell population.
  2. To dissociate adherent cells, briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C

Subculture Ratio: 1:3 to 1:6
Medium Renewal: 2 to 3 times a week.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.
Culture medium, 95%; DMSO, 5%
STR Profile
Amelogenin: X,Y
CSF1PO: 13
D13S317: 11
D16S539: 10,14
D5S818: 12
D7S820: 10,11
THO1: 7,9
TPOX: 11
vWA: 17,18
Population Doubling Time 39 hrs
Name of Depositor J Park
Deposited As Homo sapiens
Year of Origin 1990

Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation

This line is available under the following restrictions: 1.) The cell line was deposited for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2.) Any proposed commercial use of these cells or products produced by them must first be negotiated with Jae-GaHB-Park, Director, Korean Cell Line Bank, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea. Telephone (02) 760-3380, Fax (02) 742-4727. 3.) In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publication (Int. J. Cancer 62:276-282, 1995).


Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080